Amarantus CEO Gerald Commissiong Elected to Biotechnology Industry Organization Committees

SAN FRANCISCO and GENEVA, Oct. 20, 2014 (GLOBE NEWSWIRE) — Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for Alz…Read More »

Amarantus Applies to FDA for MANF Orphan Drug Designation in Retinitis Pigmentosa

SAN FRANCISCO and GENEVA, Oct. 16, 2014 (GLOBE NEWSWIRE) — Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for Alz…Read More »

Amarantus Announces Positive LP-002 Data for Alzheimer's Blood Diagnostic LymPro Test(R)

SAN FRANCISCO and GENEVA, Oct. 9, 2014 (GLOBE NEWSWIRE) — Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on developing diagnostics and therapeutics for Alzheimer’s…Read More »

Amarantus Investigator Presents Positive MANF Animal Data in Central Retinal Vein Occlusion and Glaucoma at the Targeting Ocular Disorders Conference

Data Indicates MANF Promise for Ocular Indications SAN FRANCISCO and GENEVA, Oct. 7, 2014 (GLOBE NEWSWIRE) — Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on devel…Read More »

Amarantus Requests Pre-IND Feedback From FDA for Eltoprazine Phase IIb Parkinson's Disease Levodopa-Induced Dyskinesia Clinical Trial

SAN FRANCISCO and GENEVA, Sept. 29, 2014 (GLOBE NEWSWIRE) — Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the development of diagnostics and therapeutics for Al…Read More »
Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) is a biotechnology company discovering and developing treatments and diagnostics for diseases associated with neurodegeneration and apoptosis (programmed cell death).

Company Information

Company Website: http://www.amarantus.com/
Company Headquarters

c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107
Phone: (408) 737-2734
Fax: (408) 852-4427
info@amarantus.com

Media and Investor Relations Contact

Aimee Boutcher, Director of Investor Relations
Phone: (408) 737-2734 x 101
ir@amarantus.com

Forward Looking Statements

Certain statements, other than purely historical information, including estimates, projections, statements relating to our business plans, objectives, and expected operating results, and the assumptions upon which those statements are based, are forward-looking statements." These forward-looking statements generally are identified by the words believes," project," expects," anticipates," estimates," intends," strategy," plan," may," will," would," will be," will continue," will likely result," and similar expressions. Forward-looking statements are based on current expectations and assumptions that are subject to risks and uncertainties which may cause actual results to differ materially from the forward-looking statements. Our ability to predict results or the actual effect of future plans or strategies is inherently uncertain. Factors which could have a material adverse effect on our operations and future prospects on a consolidated basis include, but are not limited to: changes in economic conditions, legislative/regulatory changes, availability of capital, interest rates, competition, and generally accepted accounting principles. These risks and uncertainties should also be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements.

This Blog is official and sanctioned by Amarantus BioScience | See Disclaimer | See Privacy Policy

Get Amarantus BioScience Blog Post Alerts